Eisai, Inc. voluntarily withdrew the weight loss medication Belviq and Belviq XR (lorcaserin) from the U.S. market following a U.S. Food and Drug Administration request. Data showed that patients who had taken the drug as part of a large clinical safety trial showed an increased occurrence of cancer five years later. 7.7% of the lorcaserin subjects developed cancer, compared to the placebo group. Cancers observed included pancreatic, colorectal, and lung.

Landing Pages

CAMG has thousands of spots and infomercials that can be branded for your firm. Reach out to us for the latest creative offline and online examples*.
*Examples shown are not always current examples.